Skip to main content
OpenTrials
Completed

NCT Number: NCT05163405

Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.

In the present study, we have trained 10 patients in subcutaneous self-administration of Velcade. After their training, patients will alternately receive their treatment in the hospital and at home by self-administration. In keeping with common practice, a nurse contacts the patients by telephone before 9.00 am on the day of treatment to ensure that the patient is physically "fit" to receive the medication and to discuss any side effects. To highlight the advantages and disadvantages of the changed treatment practice from the perspectives of both patients and healthcare professionals, data is collected from two consecutive semi-structured interviews with n = 10 patients and n = 1 focus group interview of the healthcare professionals involved. Moreover, time registration of medication administration both at the hospital and in the patients' home is done. The qualitative data will be analyzed via the method of condensation and continual quantitative data will form the basis of a cost-benefit analysis.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must have Multiple Myeloma
  • Patients (or their relatives) must be deemed physically and cognitively suitable and willing for self-administration of subcutaneous Velcade
  • Patients must be able to understand and speak Danish
  • Patients must have received a minimum of 1 treatment cycle in the outpatient clinic

Exclusion criteria

  • Lack of willingness to participate in scheduled interviews
  • Patients who are cognitively affected
  • Must not be receiving trial treatment

Treatment and study plan

bortezomib

Drug

Self-administration of subcutaneously Velcade.

Other names: Velcade

Primary outcomes

  1. Patients experience of self-administration of Velcade

    Time frame: Through study completion, from 01. dec. 2019 until 01. jun. 2022

    Qualitative interviews with all 10 included patients

Secondary outcomes

  1. Organizational perspective

    Time frame: Through study completion, from 01. dec. 2019 until 01. jun. 2022

    Patients and health professionals (including pharmacy staff) registration of time spend on treatment on all 10 included patients.

  2. Health care perspective

    Time frame: Through study completion, from 01. dec. 2019 until 01. jun. 2022

    Focus group interview with healthcare professionals involved in the treatment.

  3. Financial perspective

    Time frame: Through study completion, from 01. dec. 2019 until 01. jun. 2022

    Evaluation of financial savings on home treatment including healthcare salaries and transportation.

Sponsors and collaborators

Lead sponsor

Karin B. Ø. Dieperink

Other

Registry information

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Dec 20, 2021
Registry last updated
Aug 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.